Interchangeability, immunogenicity and biosimilars

Nat Biotechnol. 2012 Dec;30(12):1186-90. doi: 10.1038/nbt.2438.
No abstract available

MeSH terms

  • Biosimilar Pharmaceuticals* / adverse effects
  • Biosimilar Pharmaceuticals* / pharmacokinetics
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Biotechnology
  • Drug Approval / legislation & jurisprudence
  • European Union
  • Humans
  • Risk Management
  • Therapeutic Equivalency

Substances

  • Biosimilar Pharmaceuticals